Humacyte

Public

Durham, North CarolinaBiotechhttps://www.humacyte.com

Humacyte is now publicly traded

The data on this page reflects Humacyte's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Debt

Dec 16, 2025

Total Funding Raised

$696.15M

Company Overview

Humacyte operates in Biotech and is based in Durham, North Carolina. It has raised $696.15M.

Humacyte (NAS: HUMA) is a biotechnology company focused on creating universally implantable bioengineered human tissues and organs to enhance patient outcomes and revolutionize medical practices.

Sector

Biotech

AI Layer

Non-AI

Humacyte Comparables

Compare Humacyte with similar companies based on industry and business-model similarity.

Humacyte comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Elutia Inc.	79%	Demo
Xeltis	77%	Demo
Vascudyne	74%	Demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Humacyte Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Debt	Dec 16, 2025	Demo	Demo	Demo	Demo
Private Placement	Oct 8, 2025	Demo	Demo	Demo	Demo
Debt	May 12, 2023	Demo	Demo	Demo	Demo
Reverse Merger	Aug 26, 2021	Demo	Demo	Demo	Demo
Strategic	Jun 11, 2018	Demo	Demo	Demo	Demo
Grant	Sep 28, 2017	Demo	Demo	Demo	Demo

Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Humacyte Investors

Notable investors and investment history

Humacyte investors
Investor	Rounds
Access Industries	Series B
U.S. Department of Defense	Grant
Avenue Capital Group	Debt
UBS O'Connor	Reverse Merger
OrbiMed	Reverse Merger
Bangkok Bank	Series B
California Institute for Regenerative Medicine	Grant

Book a demo to see all 12 investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

has_revenue_increased_byNov 11, 2026
Humacyte increases Symvess revenue by 151% sequentially to $1.0 million in Q3 '26.
has_revenue_increased_byNov 10, 2026
Humacyte reports $1.0 million in Symvess product revenue, up 45.5% year over year in Q3 '26, with strong sequential acceleration.
has_revenueNov 10, 2026
Humacyte reports $800K in Symvess sales in October 2026, after Symvess sales reach $1.0 million in Q3.
has_revenueNov 10, 2026
Humacyte reports $1M in Symvess product revenue for Q3 '26.
attends_eventNov 3, 2026
Humacyte presents its regenerative medicine technology in three presentations at the American Heart Association Scientific Sessions 2026, including an invited talk by Founder, President and CEO Laura Niklason and presentations on its investigational coronary tissue engineered vessel, from Nov 6th-9th '26 in Illinois.